M.D. Anderson International España SA

Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1 study, targeted for 2025 FORT LAUDERDALE, FL, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma company dedicated to advancing ovarian cancer treatment through innovative drug development, today announced the formation of its Scientific Advisory Board and inaugural appointment of Dr. Anil Sood. Craig Pierson, Founder and Chairman of Kaida BioPharma commented, “As we continue on our development pathway forward, we are pleased to bolster our development program with the formation of this Scientific Advisory Board and add the renowned knowledge and expertise of Dr. Sood as its inaugural member. We believe Dr. Sood’s perspective and insight will be invaluable as we advance our clinical and regulatory strategies forward. We remain focused on executing on the development for KAD101 and potentially provide a much-needed solution for gynecologic cancers.” Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at The University of Texas MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and Co-leads the Ovarian Cancer Moon Shot Program at MD Anderson. Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill, North Carolina. A major and consistent theme of his scientific research has been on understanding human cancer biology and converting lab discoveries into novel therapeutics. His research group has made seminal research contributions in the fields of tumor microenvironment, nanomedicine, and neuroendocrine effects on cancer biology. Dr. Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), and the Association of American Physicians (AAP). He was appointed as an American Cancer Society Professor in 2017. Kaida is advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women. The Company’s lead program, KAD101 is a novel biologic that blocks the prolactin receptor to prevent cancer cell growth signals and incite autophagy initially targeting ovarian cancer. KAD101 has demonstrated encouraging results in a human clinical study with all patients showing tumor reduction with a clean safety profile as a daily injectable. The Company continues to progress the development of KAD101 toward the launch of its Phase 1 study, expected to commence in 2025. Additionally, the Company is advancing KAD102, an enhanced pure antagonist of KAD101, for the treatment of uterine cancer. About Kaida BioPharma Kaida BioPharma was founded on the research principles and clinical evidence of KAD101 (Originally G129R), a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit kaida-biopharma.com. Investor ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@jtcir.com

Plus, news about Centessa, Autolus Therapeutics, Zucara Therapeutics, Vindur Tx, Vittoria Biotherapeutics and the MD Anderson Cancer Center: Apollo Therapeutics’ cardio-metabolic pact: The company will pay $12 million upfront and up to $926 million in biobucks for worldwide rights, excluding China, to Sunshine Lake Pharma’s FGF21/GLP-1 dual receptor agonist. The drug, known as APL-18881 or HEC88473, is in Phase 2 for type 2 diabetes. — Kyle LaHucik Abeona Therapeutics’ rare skin disease gene therapy gets a second chance: The FDA set a deadline of April 29 to decide whether to approve pz-cel, Abeona’s gene therapy for recessive dystrophic epidermolysis bullosa. The regulator in April rejected Abeona’s application for pz-cel over manufacturing. — Lei Lei Wu Centessa ends work on late-stage drug: The biotech is stopping clinical development of its hemophilia drug, called SerpinPC. It had expected to have an interim analysis from a registrational trial this year. Centessa said the move would save the company $200 million, which will now be directed toward work on OX2R agonism. — Kyle LaHucik Autolus Therapeutics gets $30M payout from Blackstone: The London-based biotech received the milestone payment after the FDA last week greenlit its CAR-T cell therapy, called Aucatzyl, for relapsed and refractory B-cell acute lymphoblastic leukemia. — Ayisha Sharma Zucara Therapeutics gets $20M: Sanofi is investing in the Toronto startup’s Series B, and the French pharma gets an exclusive right to first negotiation. The money will support Zucara’s ongoing Phase 2a for an experimental once-daily medicine to prevent hypoglycemia. — Kyle LaHucik Vindur Tx inks AI deal: The startup will pay $17.5 million to digital biology company Optic to access its generative AI platform, with the goal of finding new selective kinase inhibitors for cancer drugs. — Kyle LaHucik UPenn cell therapy spinout gets $10M: Vittoria Biotherapeutics announced the extension round, which was led by Valley Forge Investment Corporation, and adds to the $15 million it raised last year. The company is studying a cell therapy for T cell lymphoma that uses gene editing to boost immune response. — Lei Lei Wu MD Anderson Cancer Center launches cell therapy institute: The organization will be led by NK cell therapy pioneer Katy Rezvani. MD Anderson has raised $80 million for the cell therapy institute so far, and it has a goal of bringing in $150 million. — Lei Lei Wu

MARTINSRIED, Germany I September 16, 2024 I Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, today announced that the first patient has been dosed in Module 1 of the ongoing Phase 1/2 MATCH clinical trial (NCT06525298) investigating the small molecule ALC1 inhibitor EIS-12656 in solid tumors. In this trial, Eisbach seeks to assess the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of the allosteric ALC1 inhibitor in the monotherapy setting. The trial, which is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson), is co-funded with an investment from the Cancer Focus Fund, a unique investment fund established in collaboration with MD Anderson to provide funding and clinical expertise to advance promising cancer therapies. EIS-12656 is a first-in-class, selective, potent, oral and brain-penetrant small molecule inhibitor of the chromatin helicase ALC1 (CHD1L), a key molecular machine involved in DNA damage and genome repair mechanisms. EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. Eisbach’s preclinical in vivo data with EIS-12656 showed rapid tumor growth inhibition, high bioavailability and excellent tolerability. “This milestone marks Eisbach’s entry into the cancer clinic with a transformative target and unique allosteric approach. ALC1 is a superior, orthogonal target in tumors with impaired DNA damage and repair. Its inhibitor EIS-12656 is the result of our ability to disrupt the function of the powerful machines that reorganize our genome in a very targeted manner,” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach. “This clinical study will assess the impact of EIS-12656’s ability to hit both genetic and molecular vulnerabilities in our cancer indications, potentially enabling its advancement as a drug that is both efficacious and well-tolerated.” About the Phase 1/2 Clinical Trial The open label study of EIS-12656 will evaluate its safety, tolerability and efficacy in patients with genetically-defined advanced solid tumors. Led by Principal Investigator Timothy A. Yap, M.B.B.S., Ph.D., Vice President, Head of Clinical Development in the Therapeutics Discovery Division and Professor of Investigational Cancer Therapeutics at MD Anderson, the trial includes dose escalation of EIS-12656 monotherapy, followed by dose expansion modules and evaluation in gynecological, pancreatic and prostate cancer patients progressing under PARP inhibitor treatment. Eisbach selected CTI Clinical Trial & Consulting, a global full-service Contract Research Organization, as a strong partner providing regulatory and clinical trial management service for this trial. About Eisbach Eisbach is at the forefront of precision oncology, developing allosteric drugs that selectively disrupt molecular machines vital for tumor genome reorganization. Combining genetic vulnerabilities with its proprietary ALLOS platform, which hits the molecular vulnerability of its cancer targets, Eisbach pioneers first-in-class therapies with fewer side effects. For more information, visit http://www.eisbach.bio and follow us on LinkedIn . SOURCE: Eisbach Bio